MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions.
MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions.
复制标题
MEK抑制剂-神经纤维瘤病相关良性和恶性病变的新型靶向治疗。
DOI:
10.1186/s40364-021-00281-0
复制
发表时间:
2021-04-16
影响因子:
11.1
通讯作者:
Harder A
中科院分区:
文献类型:
--
作者:
Harder A
MAP/ERK kinase 1 and 2 (MEK 1/2) inhibitors (MEKi) are investigated in several trials to treat lesions that arise from pathogenic variants of the Neurofibromatosis type 1 and type 2 genes (NF1, NF2). These trials showed that MEKi are capable to shrink volume of low grade gliomas and plexiform neurofibromas in NF1. Targeting other lesions being associated with a high morbidity in NF1 seems to be promising. Due to involvement of multiple pathways in NF2 associated lesions as well as in malignant tumors, MEKi are also used in combination therapies. This review outlines the current state of MEKi application in neurofibromatosis and associated benign and malignant lesions.
登录
查看更多内容
DOI:
10.1056/nejmoa1605943
发表时间:
2016-12-29
期刊:
The New England journal of medicine
影响因子:
--
作者:
Dombi E;Baldwin A;Marcus LJ;Fisher MJ;Weiss B;Kim A;Whitcomb P;Martin S;Aschbacher-Smith LE;Rizvi TA;Wu J;Ershler R;Wolters P;Therrien J;Glod J;Belasco JB;Schorry E;Brofferio A;Starosta AJ;Gillespie A;Doyle AL;Ratner N;Widemann BC
通讯作者:
Widemann BC
影响因子:
9.9
作者:
Dombi, Eva;Ardern-Holmes, Simone L.;Widemann, Brigitte C.
通讯作者:
Widemann, Brigitte C.
影响因子:
15.9
作者:
Fuse, Marisa A.;Dinh, Christine T.;Fernandez-Valle, Cristina
通讯作者:
Fernandez-Valle, Cristina
DOI:
10.1002/ajmg.a.34359
发表时间:
2012-01-01
期刊:
American journal of medical genetics. Part A
影响因子:
--
作者:
Blakeley, Jaishri O;Evans, D Gareth;Giovannini, Marco
通讯作者:
Giovannini, Marco
影响因子:
3.9
作者:
Goutagny, Stephane;Raymond, Eric;Kalamarides, Michel
通讯作者:
Kalamarides, Michel